Hong Kong-Listed ETFs

ChinaAMC Hang Seng Hong Kong Biotech Index ETF (3069 HK / 9069 HK)

Management fee

0.50%(p.a.)

4557

Listing Date

18-Mar-2021

Morningstar

/5

Fund Performance

-39.54%

YTD

-53.3%

1 Year

-

3 Year

-

5 Year

-58.28%

Since Inception

As of 30-09-2022

Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Hong Kong Biotech Index ETF (the “Fund”), investor should refer to the Fund’s prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

• The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the Hang Seng Hong Kong-Listed Biotech Index (the “Index”).
• The Fund is passively managed. Falls in the Index are expected to result in corresponding falls in the value of the Fund.
• The Fund’s investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors.
• The Index is a new index. The Fund may be riskier than those tracking more established indices with longer operating history.
• The Fund is subject to concentration risks in biotech companies and in a particular geographical region (i.e. Hong Kong and mainland China). The Fund may be more volatile than a broadly-based fund.
• The Fund is exposed to risks associated with characters of biotech companies, such as pre-revenue, incurrence of net current liabilities, lower liquidity, higher volatility, dependency on intellectual property rights or patents, technological changes, increased regulations and intense competition.
• The Fund is subject to securities lending transactions risks, including the risk that the borrower may fail to return the securities in a timely manner.
• The Fund is subject to tracking error risk.
• If any suspension of the inter-counter transfer of units and/or any limitation on the level of services by brokers and CCASS participants occurs, unitholders will only be able to trade their units in one counter. The market price of units traded in each counter may deviate significantly.
• Unitholders will receive distributions in the HKD only. Non HKD based unitholder may have to bear bank or financial institution fees and charges associated with currency conversion.
• The Fund’s base currency is HKD but has units traded in USD. Investors may be subject to additional costs or losses associated with foreign currency fluctuations.
• Generally, retail investors can only buy or sell units of the Fund on the SEHK. The trading price of the units on the SEHK is driven by market factors such as the demand and supply of the units. Therefore, the units may trade at a substantial premium or discount to the Fund’s NAV.

Product Details

Investment Objective

The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Hong Kong-Listed Biotech Index.

Product Overview

Underlying Asset Class Equity
Listing Date 18-03-2021
Base Currency HKD
Net Asset Value (mil) 654.59
Domicile Hong Kong
Management Fee 0.5%(p.a.)
Trustee and Registrar HSBC Institutional Trust Services (Asia) Limited
Distribution Policy Annually (usually in December), subject to the Manager’s discretion. All Units will receive distributions in HKD only.

As of 30-09-2022

Intra-day Estimated NAV and Market Price ( 2,3 )

Latest Market Information ( 4,5 )

Date Last Change Change(%)
Official NAV per Unit in HKD30-09-202210.07-0.03-0.31
NAV per Unit in USD (for reference only)30-09-20221.280.00-0.32
Closing Price for HKD Traded Unit30-09-202210.050.000.00
Closing Price for USD Traded Unit30-09-20221.280.000.00

Trading Information

HKD Traded UnitsUSD Traded Units
Exchange ListingSEHK – Main BoardSEHK – Main Board
Commencement of Dealing18-Mar-202130-Jun-2021
Stock Code30699069
Trading Board Lot Size100 Units100 Units
Trading CurrencyHKDUSD
SEDOL CodeBMXC534BM9CF49
Reuters Code3069.HK9069.HK
ISIN CodeHK0000711199HK0000744208
Bloomberg Ticker3069 HK9069 HK
Bloomberg NAV3069NAV9069NAV
Bloomberg iNAV3069IV9069IV
Bloomberg Shares Oustanding3069SHO9069SHO

Index Information ( 6 )

IndexHang Seng Hong Kong-Listed Biotech Index
Index ProviderHang Seng Indexes Company Limited
CurrencyHKD
Closing Level1103.28
Change-3.46
Change (%)-0.31%
Type of IndexNet Total Return

As of 30-09-2022

Participating Dealers

  • ABN AMRO Clearing Hong Kong Limited
  • BNP Paribas Securities Services
  • China International Capital Corporation (Hong Kong) Limited
  • China Merchants Securities (HK) Co Ltd
  • Citigroup Global Markets Asia Limited
  • Credit Suisse Securities (Hong Kong) Limited
  • Goldman Sachs (Asia) Securities Limited
  • Guotai Junan Securities (Hong Kong) Limited
  • Haitong International Securities Group Limited
  • Huatai Financial Holdings (Hong Kong) Limited
  • J.P. Morgan Broking (Hong Kong) Limited
  • Korea Investment & Securities Asia Limited
  • Mirae Asset Securities (HK) Limited
  • The Hongkong and Shanghai Banking Corporation Limited

Market Makers

HKD CounterUSD Counter
Flow Traders Hong Kong LimitedFlow Traders Hong Kong Limited
Haitong International Securities Company Limited
HSBC Securities Brokers (Asia) Limited
Vivienne Court Trading Pty. Ltd.

Please refer to the Hong Kong Exchanges and Clearing Limited’s website at www.hkex.com.hk for the latest lists of Market Makers.

1    Data are provided by ICE Data Indices, LLC (“ICE DATA”), is used with permission. ICE DATA, its Affiliates and their respective third party suppliers (including but not limited to Factset Research System, Inc.) disclaim any and all warranties and representations, express and/or implied, including any warranties of merchantability or fitness for a particular purpose or use, including the index data and any data included in, related to, or derived therefrom. Neither ICE DATA, its Affiliates nor their respective third party suppliers shall be subject to any damages or liability with respect to the adequacy, accuracy, timeliness or completeness of the Index data or any component thereof, and the index data and all components therefore are provided on an “as is” basis and your use is at your own risk. ICE DATA, its Affiliates and their respective third party suppliers do not sponsor, endorse, or recommend China Asset Management (Hong Kong) Limited, or any of its products or services.

2    Intra-day Estimated NAV per Unit calculations are performed by ICE DATA.

3    Intra-day Market Price refers to the market price of ChinaAMC Hang Seng Hong Kong Biotech Index on the date and at the time specified above, quoted from the Stock Exchange of Hong Kong Limited (the“SEHK”).

4    Change of the Official NAV per Unit in HKD indicate the change of the NAV per Unit since previous Dealing Day^. Please refer to the Prospectus for more information on the determination of the NAV.

5    TChanges of the Closing Price for HKD traded Units indicate the change of the closing price since previous SEHK trading day. Source of Closing Price: Bloomberg.

6   Benchmark Index returns are for illustrative purposes only and are not indicative of future results. Benchmark Index returns do not reflect any management fees, transaction costs or expenses. Change indicates the change since the last closing index level. Source: HSI, Bloomberg (see Terms and Conditions).

^ “Dealing Day” generally means a day on which (a) the SEHK is open; and (b) the Index is compiled and published. Please refer to the Prospectus for further details in this regard.

Performance Chart

Fund Price

Class Currency Dealing Date NAV per unit
HKD HKD 30-09-2022 10.0707
USD USD 30-09-2022 1.2829

Since Launch Performance

Returns
Historical NAVs
HKD
HKD

ETF listing date: 18 March 2021

With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply.

Investment involves risks. Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested. These figures show by how much the Fund increased or decreased in value during the calendar year being shown. Performance data has been calculated in the base currency of the share class (or the ETF), including ongoing charges and excluding subscription and redemption fees and trading costs on SEHK (if applicable). Where no past performance is shown there was insufficient data available in that year to provide performance. Please refer to the Fund Overview section for the inception date of the share class (or the listing date of the ETF).

Holdings

Top 10 Holdings

Holdings. Weighting (%)
CHINA PHARMACEUTICAL GROUP 10.96
WUXI BIOLOGICS CAYMAN INC 8.17
JD HEALTH INTERNATIONAL INC 7.9
SINO BIOPHARMACEUTICAL 6.56
INNOVENT BIOLOGICS INC 5.08
SHANDONG WEIGAO GP MEDICAL-H 4.14
ZAI LAB LTD 3.95
WUXI APPTEC CO LTD-H 3.53
GENSCRIPT BIOTECH CORP 3.42
SINOPHARM GROUP CO-H 3.33
Total 57.04

As of 30-09-2022

Holding Details

Click below button to show the details of the holdings

Holdings are subject to change. Total allocation percentages shown in the Holdings table may not equal 100% due to rounding,  The historical data provided herein is for reference only and does not represent any future performance.

Sector Breakdown

As of 30-09-2022

Country Breakdown

As of 30-09-2022

Yield Information

There is currently no information available.

Asset Allocation

Asset Typs Weighting(%)
Health Care 88.68%
Consumer Discretionary 10.96%

As of 30-09-2022

Tracking Difference & Error

Tracking Difference (TD):

Tracking difference is the return difference between the ETF and its underlying benchmark/ index over a certain period of time.

Tracking Error (TE):

Tracking error measures how consistently the ETF follows its benchmark/ index. It is the volatility (measured by standard deviation) of that return difference.

Tracking Difference / Tracking Error

Rolling 1-Year TD0.30%
Rolling 1-Year TE^0.42%

As of 31-08-2022

^Annualized based on the number of dealing days in the last year when daily TD is calculated

Graph for Tracking Difference

Calendar Year Performance (#)​

#The benchmark of the ETF is Hang Seng Hong Kong-Listed Biotech Index

 

Past performance Vs Benchmark performance

ETF listing date: 18 March 2021

With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply.

Investment involves risks. Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested. These figures show by how much the Fund increased or decreased in value during the calendar year being shown. Performance data has been calculated in the base currency of the share class (or the ETF), including ongoing charges and excluding subscription and redemption fees and trading costs on SEHK (if applicable). Where no past performance is shown there was insufficient data available in that year to provide performance. Please refer to the Fund Overview section for the inception date of the share class (or the listing date of the ETF).

Distribution History

There is currently no information available.

Prospectus & Documents

Factsheet
Financial Reports
Fund Brochure
Offering Documents
File name Date File Format
Factsheet - August 2022 16-09-2022 PDF >
Fund Factsheet 15-08-2022 PDF >
File name Date File Format
Unaudited Semi-annual Report 2022 16-08-2022 PDF >
2021 Annual Report 20-04-2022 PDF >
File name Date File Format
Brochure 17-03-2021 PDF >
File name Date File Format
Product Key Facts 08-04-2022 PDF >
Prospectus 08-11-2021 PDF >

Announcements & Notices

Investing involves risk, including possible loss of principal. Investment in emerging market countries may involve heightened risks such as increased volatility and lower trading volume, and may be subject to a greater risk of loss than investment in a developed country. Please carefully consider the Fund’s investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the relevant Fund’s prospectus. Please read the prospectus carefully before investing. ChinaAMC Funds are not sponsored, endorsed, issued, sold or promoted by their index providers (only applicable to ETFs and index funds). For details of an index provider including any disclaimer, please refer to the relevant ChinaAMC Fund offering documents.

Source: Fund performance and index data are provided by ChinaAMC and the relevant index providers (if applicable) respectively.

This website is prepared by China Asset Management (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission.

FAQs

FAQs

Remarks
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.

Performance Simulator

Performance Simulator

Please select the simulation period

Start date:

End date:

Simulation Results

The Product

0%

Index

0%

Leverage/Inverse

0%

Performance Chart

Remarks
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.

重要提示:

重要提示:

Private Funds

ChinaAMC(HK) is uniquely positioned in the market which enables it to leverage its extensive knowledge, research capabilities and investment experience in China to deliver a range of high-value asset management or investment advisory services to institutional clients worldwide. To bridge overseas investors with China opportunities, ChinaAMC (HK) is committed to utilize its local expertise to capture enormous investment potentials in China.

The private fund products issued and managed by ChinaAMC (HK) include Cayman Islands registered funds and Luxembourg domiciled SICAV funds*.

Browse through our website and discover our investment strategies. For private fund products information, please visit the product page by logging into your account.

* SICAV fund is an open-ended collective investment scheme common in Western Europe and may be open to public investors in certain European countries depending on its registration status.

Welcome back

Lorem ipsum dolor sit amet, conse ctetuer adipi scing elitenean.